{
    "clinical_study": {
        "@rank": "105988", 
        "acronym": "OsvaRen-NEW", 
        "arm_group": [
            {
                "arm_group_label": "Osvaren Granules", 
                "arm_group_type": "Experimental", 
                "description": "Osvaren Granules"
            }, 
            {
                "arm_group_label": "Osvaren film-coated tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "Osvaren film-coated tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "Phosphate binders are crucial to the control of elevated phosphate levels in patients with\n      chronic kidney disease. With the new formulation of granules the pill burden of patients is\n      sought to be reduced.\n\n      This study is about efficacy and safety of the new drug formulation and compares it to the\n      \"old\" formulation which are film-coated tablets."
        }, 
        "brief_title": "Therapeutic Equivalence of OsvaRen\u00ae Tablets and OsvaRen\u00ae Granules", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hyperphosphatemia", 
            "Chronic Kidney Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Hyperphosphatemia", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is aimed at demonstrating the therapeutic equivalence of both products, i.e.\n      granules versus tablets.\n\n      Secondary objectives are: Comparing both preparations with regard to the number of patients\n      reaching serum phosphate levels < 1.76 mmol/L and the difference in serum phosphate levels\n      between the first and last visit under each treatment. Furthermore, it is the aim of this\n      study to evaluate the safety profile of OsvaRen\u00ae granules in comparison to OsvaRen\u00ae tablets.\n      Especially serum calcium, magnesium, and PTH are of interest."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed written informed consent form is obtained prior to starting the screening\n             visit\n\n          -  Male and female patients 18-80 years of age with dialysis dependent renal failure\n             (CKD 5D)\n\n          -  Patients have been on 3x/week in-centre renal replacement therapy for at least 2\n             months on either low-flux or high-flux HD or OL-\n\n             /HDF\n\n          -  Prescribed haemodialysis session duration is \u2265 4 hours\n\n          -  spKt/V \u2265 1.20 according to last in-centre measurement prior the study enrolment\n\n          -  Patients have been on OsvaRen\u00ae tablets for at least 12 weeks as sole phosphate binder\n             and the titration phase has been completed according to physician\u00b4s discretion\n\n          -  Patients are able to take the study medication as prescribed particularly OsvaRen\u00ae\n             stickpacks\n\n          -  Patients are willing to stop any calcium, magnesium or vitamin D containing\n             supplements\n\n          -  Patients are willing to maintain their typical diet with regards to phosphate uptake\n             for the time of the study\n\n          -  Patients are willing to comply with the study protocol\n\n        Exclusion criteria\n\n          -  Pregnant women (by blood \u00df-hCG pregnancy test) or women breast-feeding or unwilling\n             to use contraceptive measures during the entire course of the study or\n\n          -  Patients with a life expectancy shorter than the planned duration of the study or\n\n          -  Patients with any acute or chronic severe disease potentially interfering with study\n             outcomes or\n\n          -  Patients with PTH levels > 800 ng/l or\n\n          -  Patients who participated in an interventional clinical study during the preceding 30\n             days or\n\n          -  Patients suffering from any other, not mentioned condition which could interfere with\n             the patient's ability to comply with the study or\n\n          -  Patients who previously participated in the same study are excluded from the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027662", 
            "org_study_id": "RP-OSV-02-D"
        }, 
        "intervention": [
            {
                "arm_group_label": "Osvaren Granules", 
                "intervention_name": "Osvaren Granules", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Osvaren film-coated tablets", 
                "intervention_name": "Osvaren film-coated tablets", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "J\u00fcrgen Floege, MD"
                }, 
                "contact_backup": {
                    "last_name": "Michael Moeller, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Aachen", 
                        "country": "Germany", 
                        "state": "NRW", 
                        "zip": "52074"
                    }, 
                    "name": "RWTH University Hospital, Dpt for Nephrology"
                }, 
                "investigator": {
                    "last_name": "J\u00fcrgen Floege, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christoph Haufe, MD"
                }, 
                "contact_backup": {
                    "last_name": "Ines Solf, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Erfurt", 
                        "country": "Germany"
                    }, 
                    "name": "Nephro-Studien GbR am Klinikum Erfurt"
                }, 
                "investigator": {
                    "last_name": "Christoph Haufe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Wolfgang Ries, MD"
                }, 
                "contact_backup": {
                    "last_name": "Stephan Schmiedel, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Flensburg", 
                        "country": "Germany", 
                        "zip": "24939"
                    }, 
                    "name": "Dialysezentrum"
                }, 
                "investigator": {
                    "last_name": "Wolfgang Ries, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kai Toussaint, MD"
                }, 
                "contact_backup": {
                    "last_name": "Rolf Schneidenbach, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "22297"
                    }, 
                    "name": "Nephrocare Hamburg-Barmbek GmbH"
                }, 
                "investigator": {
                    "last_name": "Kai Toussaint, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hans Schmidt-G\u00fcrtler, MD"
                }, 
                "contact_backup": {
                    "last_name": "Wanja Bernhardt, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany"
                    }, 
                    "name": "Dialysezentrum"
                }, 
                "investigator": {
                    "last_name": "Hans Schmidt-G\u00fcrtler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ekkehardd Ziegler, MD"
                }, 
                "contact_backup": {
                    "last_name": "Tilman David-Walek, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "zip": "24106"
                    }, 
                    "name": "Dialysezentrum"
                }, 
                "investigator": {
                    "last_name": "Ekkehard Ziegler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ute Domr\u00f6se, MD"
                }, 
                "contact_backup": {
                    "last_name": "Matthias Nielebock, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany"
                    }, 
                    "name": "Dialysezentrum"
                }, 
                "investigator": {
                    "last_name": "Ute Domr\u00f6se, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "J\u00f6rg Radermacher, MD"
                }, 
                "contact_backup": {
                    "last_name": "Ulrich Schmitz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Minden", 
                        "country": "Germany"
                    }, 
                    "name": "Dialysezentrum"
                }, 
                "investigator": {
                    "last_name": "J\u00f6rg Radermacher, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Schmitz, MD"
                }, 
                "contact_backup": {
                    "last_name": "Hans Heering, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Solingen", 
                        "country": "Germany"
                    }, 
                    "name": "Dialysezentrum"
                }, 
                "investigator": {
                    "last_name": "Michael Schmitz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Koch, MD"
                }, 
                "contact_backup": {
                    "last_name": "Sendokan Aker, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Velbert", 
                        "country": "Germany"
                    }, 
                    "name": "Dialysezentrum"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study to Investigate Efficacy and Safety Equivalence of OsvaRen\u00ae Tablets and OsvaRen\u00ae Granules", 
        "overall_contact": {
            "email": "frank.laukhuf@fmc.ag.com", 
            "last_name": "Frank M Laukhuf, MD", 
            "phone": "+496172609", 
            "phone_ext": "4172"
        }, 
        "overall_contact_backup": {
            "email": "thomas.schulz@fmc-ag.com", 
            "last_name": "Thomas Schulz, PhD", 
            "phone": "+496172609", 
            "phone_ext": "5457"
        }, 
        "overall_official": {
            "affiliation": "University Aachen", 
            "last_name": "J\u00fcrgen Floege, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Non-inferiority of phosphate control by granules versus tablets. Serum phosphate levels will be measured for the primary outcome.", 
            "safety_issue": "Yes", 
            "time_frame": "After 4 weeks of treatment time"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027662"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients reaching serum phosphate levels < 1.76 mmol/L. this study to evaluate the safety profile of OsvaRen\u00ae granules. in comparison to OsvaRen\u00ae tablets. Especially serum calcium, magnesium, and PTH are of interest.", 
            "safety_issue": "Yes", 
            "time_frame": "Between the first and last visit under each treatment i.e. 4 weeks"
        }, 
        "source": "Fresenius Medical Care Deutschland GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fresenius Medical Care Deutschland GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}